comparemela.com

Latest Breaking News On - China universal asset management - Page 1 : comparemela.com

REGENXBIO (NASDAQ:RGNX) Stock Price Down 5%

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report)’s stock price traded down 5% on Monday . The stock traded as low as $13.22 and last traded at $13.38. 322,961 shares were traded during trading, a decline of 48% from the average session volume of 622,212 shares. The stock had previously closed at $14.08. Analyst Ratings Changes […]

Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Mva Investors, Llc Sells 63,000 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) insider Mva Investors, Llc sold 63,000 shares of Tango Therapeutics stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $7.24, for a total value of $456,120.00. Following the completion of the transaction, the insider now owns 420,524 […]

Q2 2024 Earnings Forecast for Prothena Co. plc Issued By Zacks Research (NASDAQ:PRTA)

Prothena Co. plc (NASDAQ:PRTA – Free Report) – Analysts at Zacks Research upped their Q2 2024 earnings per share (EPS) estimates for Prothena in a research report issued on Monday, May 27th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will earn ($1.22) per share for the quarter, up from their previous […]

TAL Education Group (NYSE:TAL) Now Covered by Analysts at HSBC

HSBC started coverage on shares of TAL Education Group (NYSE:TAL – Free Report) in a report released on Wednesday, StockNewsAPI reports. The brokerage issued a buy rating and a $16.00 price target on the stock. TAL has been the topic of several other reports. TheStreet raised shares of TAL Education Group from a d+ rating […]

HC Wainwright Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $13.00

Tango Therapeutics (NASDAQ:TNGX – Free Report) had its price target cut by HC Wainwright from $16.00 to $13.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Tango Therapeutics’ Q2 2024 earnings at ($0.36) EPS, Q3 2024 earnings […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.